(Alliance News) - PureTech Health PLC on Thursday said its affiliate Akili Interactive reported the results of its randomised, controlled trial of digital therapeutic AKL-T03.
AKL-T03 was created as a potential treatment for cognitive impairments adjunct to anti-depressant medication in adults with major depressive disorder.
In the study, PureTech said AKL-T03 demonstrated a "statistically significant" improvement in sustained attention compared to control.
Eric Elenko, chief innovation officer at PureTech, said: "We are pleased with these results as they provide additional support for the potential of Akili's proprietary digital treatment platform across multiple indications."
Shares in the clinical stage biotechnology company were trading 6.0% higher in London on Thursday afternoon at 264.00 pence each.
By Evelina Grecenko; evelinagrecenko@alliancenews.com
Copyright 2019 Alliance News Limited. All Rights Reserved.
PureTech (PRTC)